Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Suspended 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 2Lymphoma, B-Cell 2Carcinoma, Transitional Cell 2Carcinoma 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Pancreatic Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Lung Neoplasms 1Liposarcoma, Myxoid 1Leukemia, Myeloid, Acute 1Endometrial Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 121pembrolizumab 119Pemetrexed 102Cisplatin 76Paclitaxel 56osimertinib 52Nivolumab 50Docetaxel 50durvalumab 47Specimen Handling 37Gemcitabine 34Magnetic Resonance Spectroscopy 33Radiosurgery 27Cetuximab 26130-nm albumin-bound paclitaxel 26atezolizumab 25Radiotherapy 20Ipilimumab 19Drug Therapy 19Bevacizumab 19cemiplimab 17amivantamab 17Taxes 16Ramucirumab 13alectinib 12tislelizumab 11lazertinib 11Leucovorin 11Fluorouracil 11Radiation 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × ALT-803 × 90 days × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT07355205 2026-05-22

FLINN

Washington University School of Medicine

Phase 2 Not yet recruiting
26 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06745908 2026-05-05

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

ImmunityBio, Inc.

Phase 3 Recruiting
507 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡